Release date: 2010-01-05
Recently, the National 863 Program and the Guangdong Provincial Key Science and Technology Program—the world's first “new generation of human-source cell-combined bioartificial liver†were successfully developed at Zhujiang Hospital of Southern Medical University and won 9 national patents. At present, the project has successfully produced the first new bio-artificial liver prototype, which is about to enter the clinical trial stage.
Gao Yi, from the Department of Hepatobiliary, Zhujiang Hospital, said, “It is expected that in the next three to five years, this machine will enter the clinical application stage and become a real life-saving machine. A bioreactor with a capacity of about 3 liters can raise about 10 The 10th to 10th hepatocytes from 9th to 10th can be used for one patient for at least 3 to 5 days, and the cost is about 10,000 to 20,000 yuan.
For patients with severe hepatitis and liver failure, the current domestic treatment methods are mainly medical treatment and liver transplantation, but the drug treatment effect is not satisfactory, and the mortality rate is as high as 80% to 90%. Today, about 300,000 to 500,000 patients die each year from liver failure in China. Shanghai Medical Device Industry Association
Pcr Medical Equipment,Pcr System Dna Analysis,Family Real Time Pcr System
Jiangsu Dinai Bioengineering Co.,ltd. , https://www.dinaipcr.com